The Latest

Press Releases

About Syncromune

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing SYNC-T, a completely in situ immunotherapy platform optimized for solid tumor cancers that combines partial oncolysis and a multi-target biologic drug infusion. The platform is designed to achieve personalized T cell activation, empowering the immune system to recognize and attack cancer throughout the body.  A Phase 2a trial of the first candidate, SV-102, is currently underway.

Syncromune in the News

Kyle LaHucik     |     Endpoints News      |     December 20, 2024

Exclusive: Florida cancer biotech raises $100M Series A

Vera Kovacevic, PhD     |     XTalks      |     September 3, 2024

Syncromune’s Innovative Approach to Solid Tumor Immunotherapy

Paul McClure      |     New Atlas      |     July 2, 2024

FDA fast-tracks personalized therapy for hard-to-treat prostate cancer

OncoDaily      |     June 20, 2024

Syncromune Announces FDA Clearance of IND Application for SYNC-T SV-102

AACR Cancer Research Catalyst      |     May 16, 2024

From the Bench, AACR Annual Meeting 2024: CAR Tregs, Bacteria-virus Duos, and More

OncologyTube      |     April 18, 2024

Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD

Ryan Cross     |     ENDPOINTS NEWS      |     April 10, 2024

Early cancer vaccine data breathe new life into the field, but many questions remain: #AACR24

The ASCO Post      |     April 9, 2024

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

Greg Slabodkin, Heather McKenzie and Tyler Patchen    |     BioSpace     |     April 9, 2024

AACR 2024: What Cancer Researchers Are Talking About

Jade Parker     |     Oncology Central     |     April 9, 2024

AACR Annual Meeting 2024: news roundup

Anette Breindl    |     BioWorld     |     April 8, 2024

AACR 24: Freezing, of all things, is one way to heat cold tumors

George Prendergast, Ph.D.   |     VJOncology     |     April 8, 2024

AACR 2024  |  Preclinical modeling of cryo-immune vaccination in solid tumors

AACR 2024  |  SYNC-T combination immunotherapy in mCRPC

AACR 2024  |  The advantages of cryo-immune vaccinations in treating metastatic cancers

BiotechTV     |     April 8, 2024

Syncromune’s AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC

American Association for Cancer Research (AACR)     |     April 7, 2024

A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer

Presentations

Piper Sandler 36th Annual Healthcare Conference     |     December 4, 2024

SYNC-T® Personalized In Situ Combination Immunotherapy

Upcoming Events

The following are meetings and conferences that the Syncromune team plans to attend.  If you would like to meet with one of our team members, please email us at info@syncromune.com

Days

Add To Calendar

April 25-30, 2025

McCormick Place

Chicago, IL

AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

Conference information: AACR 2025

Days

Add To Calendar

May 30-June 3, 2025

McCormick Place

Chicago, IL

2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

Conference information:  ASCO 2025

Days

Add To Calendar

June 16-19, 2025

Boston Convention Center

Boston, MA

BIO INTERNATIONAL CONVENTION

Conference information:  BIO 2025

Past Events

2025

January 13-16, 2025

December 4, 2024

November 6-10, 2024

May 31 – June 4, 2024

April 5 – 10, 2024

February 26 – 28, 2024

January 8 – 11, 2024

November 3 – 5, 2023

SOCIETY FOR IMMUNOTHERAPY OF CANCERS (SITC) ANNUAL MEETING

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308